My Cart

PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (0.03% Proclin)

Customer Reviews
Cat. No. / Size
Price
Qty
FABm038-01-200tests (50tests X 4)
$200.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Source

    Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 is a chimeric monoclonal antibody recombinantly produced from CHO cells, which combines the variable region of a human monoclonal antibody with mouse IgG1 constant domain, which provides higher batch consistency and long term security of supply.

  • Antibody Type

    Recombinant Monoclonal

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Rabbit

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Application

    Flow Cytometry (Detection the expression of 4-1BB on Human cells).

  • Recommended Dilution

    1:20

  • Isotype Control

    The isotype control is sold separately; please refer to Cat. No. DNP-PM1 for product information.

  • Form

    Liquid

  • Formulation

    Supplied as 0.2 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Shipping

    Liquid product is shipped at blue ice.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Store at 2-8 °C for 12 months.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-FACS

     4-1BB FACS

    Flow cytometric analysis of HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line staining with PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (Cat. No. FABm038-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells. Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain . Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4, CD8, memory CD8, NKT, and regulatory T cells as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts . It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells . This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell . It can also enhance the activation-induced cell death of repetitively stimulated T cells . Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells . 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8 T cell proliferation . Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells.
4-1BB activation enhances CD8 T cell and NK cell mediated anti-tumor immunity . It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome . Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively .

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor receptor superfamily member 9

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    77 Details

  • Highest Development Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background